ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ - Mollis Shanghai UniClub

ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ

 ÕÒ»ØÃÜÂë
 »¶Ó­¼ÓÈë һͬ×ÊѶ
http://www.danlan.org/new/UploadFile/201712/20171214/ea_20
http://www.danlan.org/new/UploadFile/201712/20171201/ea_20171211
http://www.danlan.org/new/UploadFile/20170
http://www.danlan.org/new/UploadFile/201712/20171212/ea_20171212221732992.jpg ɽÎ÷Ê¡ÎÀÉú¼

Ñо¿·¢ÏÖIbalizumab¿ÉÖÎÁƶàÒ©ÄÍÒ©ÐÔHIV¸ÐȾ

2018-8-21 11:51| ·¢²¼Õß: admin| ²é¿´: 701| ÆÀÂÛ: 0

ÕªÒª: NEJM£ºIbalizumabÓÃÓÚ¶àÒ©ÄÍÒ©ÐÔHIV¸ÐȾÕßЧ¹ûÏÔÖø¡¡¡¡¡¾ÔÆÄÏͬ־»áËù¡¿ÈËÔ´»¯IgG 4µ¥¿Ë¡¿¹ÌåIbalizumab£¬¿Éͨ¹ýÓëCD4µÄ·Ç¾ºÕùÐÔ½áºÏ£¬×è¶ÏHIV½øÈëTϸ°û¡£¡¡¡¡ÔÚ½üÈյĵ¥ÖÐÐÄIIIÆÚÁÙ´²Ñо¿ÖУ¬Ñо¿ÈËÔ±ÕÐļÁË40Ãû¶à ...

NEJM£ºIbalizumabÓÃÓÚ¶àÒ©ÄÍÒ©ÐÔHIV¸ÐȾÕßЧ¹ûÏÔÖø

¡¡¡¡¡¾ÔÆÄÏͬ־»áËù¡¿ÈËÔ´»¯IgG 4µ¥¿Ë¡¿¹ÌåIbalizumab£¬¿Éͨ¹ýÓëCD4µÄ·Ç¾ºÕùÐÔ½áºÏ£¬×è¶ÏHIV½øÈëTϸ°û¡£

¡¡¡¡ÔÚ½üÈյĵ¥ÖÐÐÄIIIÆÚÁÙ´²Ñо¿ÖУ¬Ñо¿ÈËÔ±ÕÐļÁË40Ãû¶àÖÖ¿¹²¡¶¾Ò©ÎïÄÍÒ©µÄ³ÉÄêHIV¸ÐȾÕߣ¬»¼ÕßHIV-RNA¿½±´Êý1000ÒÔÉÏ¡£¾­7ÌìÎȶ¨ÆÚºó£¬»¼Õß½ÓÊÜ2000mg Ibalizumab£¬7ÌìºóÔٴνÓÊܲ¡¶¾¿½±´Êý²âÊÔ¡£ÔÚΪÆÚ25ÌìµÄÑо¿ÖУ¬»¼Õßÿ2ÖܽÓÊÜ800mg IbalizumabÖÎÁÆ¡£Ñо¿µÄÖ÷ÒªÖÕµãÊDz¡¶¾¿½±´Êý½µµÍ0.5 log10ÒÔÉϵϼÕß±ÈÀý¡£

¡¡¡¡31ÈËÍê³ÉÑо¿£¬Æ½¾ù»ùÏß²¡¶¾¿½±´Êý4.5 log10£¬Æ½¾ùCD4¼ÆÊý150¡£7Ììºó¶þ´Î²âÊÔÏÔʾ£¬33ÈË(83%)´ïµ½Ö÷ÒªÖյ㣬ƽ¾ù²¡¶¾¿½±´Êý½µµÍ1.1 log10¡£25ÖÜʱ£¬IbalizumabÖÎÁÆ×鯽¾ù²¡¶¾¿½±´Êý½µµÍ1.6 log10£¬43%µÄ»¼Õ߯䲡¶¾¸ººÉµÍÓÚ50£¬50%µÄ»¼Õß²¡¶¾¸ººÉµÍÓÚ200¡£10Ãû»¼ÕßÖÎÁÆÊ§°Ü»ò¸´·¢£¬ÌåÍâ²âÊÔÏÔʾ9È˶ÔIbalizumabÃô¸ÐÐԽϻùÏß½µµÍ¡£20%»¼Õß³öÏÖ¸¹Ðº£¬ÊÇ×î³£¼ûµÄ²»Á¼Ê¼þ¡£4Ãû»¼ÕßËÀÓÚÆäËû»ù´¡¼²²¡£¬1Ãû»¼Õß³öÏÖÖÎÁÆÏà¹ØµÄÃâÒßÖØ½¨Ñ×Ö¢×ÛºÏÕ÷¡£

¡¡¡¡Ñо¿ÈÏΪIbalizumab¿ÉÓÐЧÖÎÁƶàÒ©ÄÍÒ©ÐÔHIV¸ÐȾ¡£

¡¡¡¡Ô­Ê¼³ö´¦£ºBrinda Emu et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med.August 16 2018.

¡¡¡¡(À´Ô´£ºMedSci)


ÏÊ»¨

ÎÕÊÖ

À×ÈË

·¹ý

¼¦µ°

×îÐÂÆÀÂÛ

Archiver|ÊÖ»ú°æ|СºÚÎÝ|ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ  

GMT+8, 2023-1-27 05:37 , Processed in 0.073004 second(s), 19 queries .

Powered by ͬ־´óȫվ¶ÔÓÚÈκΰüº¬ÓÚ¡¢¾­ÓÉ¡¢Á´½Ó¡¢ÏÂÔØ»ò´ÓÈκÎÓë±¾ÍøÕ¾ÓйطþÎñ£¨ÒÔϼò³Æ[·þÎñ]£©Ëù»ñµÃ µÄÐÅÏ¢¡¢ÄÚÈÝ»ò¹ã¸æ£¨ÒÔϼò³Æ[×ÊÁÏ]£©£¬²»ÉùÃ÷»ò±£Ö¤ÆäÕýÈ·ÐÔ»ò¿É¿¿ÐÔ¡£ÄúÓڴ˽ÓÊܲ¢³ÐÈÏÐÅÀµÈκΠ[×ÊÁÏ]Ëù·¢ÉúµÄ·çÏÕ¶¼Ó¦×ÔÐге£¡£¶ÔÓÚÒò[·þÎñ]¡¢[×ÊÁÏ]ËùÉúµÄÈκÎÖ±½Ó¡¢¼ä½Ó¡¢¸½´øµÄ»òÒò´Ë¶øµ¼Ö µÄÑÜÉúÐÔËðʧ¸Å²»¸ºÔð¡£ °²»ÕÍ¬Ö¾ÍøÕ¾ÎªÃâ·ÑÍøÖ·Õ¾£¬ËùÓÐÁ¬½Ó¾ùÀ´×ÔÍøÉÏ£¬ÆäÏà¹ØÄÚÈÝÒ»¸ÅÓë±¾Õ¾Î޹أ¬±¾Õ¾²»¶ÔÏà¹ØÍøÕ¾ÄÚÈÝ ¸ºÔð£¡ÈçÄú·¢ÏÖ±¾Õ¾ÓÐÈκηǷ¨²»Á¼Á¬½Ó,ÇëÁ¢¼´¸æÖ®ÎÒÃÇ,ÎÒÃǽ«ÔÚµÚһʱ¼äÄÚɾ³ý.ÎÒÃǼá¾öÖ§³ÖºÍÅä ºÏרÏîÐж¯ X3.2

© 2001-2013 Comsenz Inc.

·µ»Ø¶¥²¿